Orally administered lenalidomide, a second-generation antimyeloma thalidomide analog, is a workhorse in contemporary management of multiple myeloma: it is approved by the US Food and Drug Administration (FDA) for the posttransplantation treatment of newly diagnosed multiple myeloma and for postinduction maintenance therapy for patients who are not eligible for autologous stem cell transplantation (ASCT).1,2 Recently, reported findings...Continue Reading